Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non-small-cell lung cancer

Yu Wang; Tao Zhang; Yin Yang; Jianyang Wang; Canjun Li; Xin Xu; Yuqi Wu; Ying Jiang; Jinghao Duan; Luhua Wang; Nan Bi

doi:10.1002/ctm2.1619

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (3) :e1619 DOI: 10.1002/ctm2.1619

LETTER TO THE JOURNAL

Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non-small-cell lung cancer

Author information +

History +

PDF

Cite this article

Download citation ▾

Yu Wang, Tao Zhang, Yin Yang, Jianyang Wang, Canjun Li, Xin Xu, Yuqi Wu, Ying Jiang, Jinghao Duan, Luhua Wang, Nan Bi. Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non-small-cell lung cancer. Clinical and Translational Medicine, 2024, 14(3): e1619 DOI:10.1002/ctm2.1619

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Moding EJ, Liu Y, Nabet BY, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer. Nat Cancer. 2020;1(2):176-183.

[2]	Pan Y, Zhang JT, Gao X, et al. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients. Cancer Cell. 2023;41(10):1763-1773.

[3]	Wang Y, Zhang T, Huang Y, et al. Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage iii non-small cell lung cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2022;112(5):1154-1164.

[4]	Yang Y, Zhang T, Wang J, et al. The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients. Mol Cancer. 2022;21(1):117.

[5]	Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451.

[6]	Turner RC, Lucke-Wold BP, Hwang R, Underwood BD. Lung cancer metastasis presenting as a solitary skull mass. J Surg Case Rep. 2016;2016(6):1-3.

[7]	Goeckeritz J, Cerillo J, Sanghadia C, et al. Principles of lung cancer metastasis to brain. J Skeleton System. 2022;1(1):1-10.

[8]	Chu T, Yuan J, Lu J, et al. Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non-small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy. Clin Transl Med. 2023;13(6):e1277.

[9]	Assaf ZJF, Zou W, Fine AD, et al. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med. 2023;29(4):859-868.

[10]	Nabet BY, Esfahani MS, Moding EJ, et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell. 2020;183(2):363-376.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.